Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.8786
-0.0612-6.51%
Pre-market: 0.89820.0196+2.23%07:42 EDT
Volume:10.19M
Turnover:9.05M
Market Cap:243.47M
PE:-7.90
High:0.9400
Open:0.9350
Low:0.8650
Close:0.9398
52wk High:3.22
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:0.96
T/O Rate:3.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:9.73
PE(LYR):-42.27

Loading ...

Akebia Therapeutics - Voice Trial Meets Stopping Criteria with Win Odds of 1.16 as of June 1, 2026

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - no Significant Difference in Mortality: Vafseo 8.77% vs Esa 8.78% Per 100 Patient-years

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch

Simply Wall St.
·
Jun 24

Akebia Therapeutics shareholders approved authorized share increase amendment at annual meeting

Reuters
·
Jun 23

Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease

MT Newswires Live
·
Jun 10

Akebia says new Vafseo dosing patent is listed in FDA Orange Book

Reuters
·
Jun 10

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

GlobeNewswire
·
Jun 10

Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each

Reuters
·
Jun 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 02

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Akebia Therapeutics Earnings Call: Vafseo Drives Transition

TIPRANKS
·
May 20

Akebia Therapeutics Balances Vafseo Momentum With Headwinds

TIPRANKS
·
May 09

Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses

Reuters
·
May 07

Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million

Reuters
·
May 07

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Benzinga Earnings
·
May 07

Akebia Therapeutics Q1 Revenue USD 53.5 Million VS. Ibes Estimate USD 51.7 Million

THOMSON REUTERS
·
May 07

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Akebia Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 05

Akebia grants new hires options for 208,800 shares at $1.38 each

Reuters
·
May 05